Tern Plc (LON:TERN), the investment company specialising in supporting high growth, early-stage, disruptive Internet of Things (“IoT”) technology businesses, has announced that the maturity dates of the approximately £0.3 million of convertible loan notes that the Company holds in Talking Medicines Limited have been extended, with all of Tern’s CLNs in Talking Medicines being extended to 21 November 2029.
A proportion of the CLNs were due to mature on 30 November 2025 and the maturity dates of all of Talking Medicines’ outstanding CLNs have now been extended, together with the terms and conditions of the various tranches of Talking Medicines CLNs being equalised, to reflect the CLN terms described in Tern’s announcement of 1 February 2024. The Tern directors believe that this will place Tern in a more advantageous negotiating position with regard to any exit from Tern’s holding in Talking Medicines.
Tern Plc specialises in identifying and supporting early-stage IoT companies with disruptive potential, aiming to generate substantial shareholder value through strategic investment and active support.
